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Abstract 
Over-expression of inflammation associated enzyme cyclo-oxygenase (COX)-2 promotes 
breast cancer progression, metastasis and sustains cancer stem-like cells (SLCs) by activating 
prostaglandin E2 receptor EP4. Two COX-2 induced oncogenic miRNAs, miR-655 and miR-
526b, target and down-regulate the cytoplasmic polyadenylation element binding protein 
(CPEB)-2. Hypothesis: Down-regulation of CPEB2 promotes an aggressive breast cancer 
phenotype through SLC induction and epithelial to mesenchymal transition (EMT). We 
found that high COX-2/miRNA expressing cell lines MDAMB231 and MCF7-COX-2 had 
significantly lower expression of CPEB2 than MCF7 cells (low COX-2/miRNA). CPEB2 
knockdown (KD) in CPEB2-high MCF7 cell line resulted in increased migratory and 
invasive capacity in vitro. CPEB2 KD increased spheroid forming ability (SLC surrogate), 
expression of SLC markers (Nanog, ALDH1, SOX-2), and mesenchymal marker (Twist1), 
and decreased epithelial marker (E-Cadherin). Furthermore, treatment with COX-2 inhibitor 
and EP4 antagonist increased CPEB2 expression. Collectively, CPEB2 demonstrates anti-
oncogenic functions and CPEB2 inhibition promotes an aggressive breast cancer phenotype. 
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1.1 Overview of Cancer 
Cancer is a disease that starts in the cells of various tissues in the body. Cancer cells 
acquire mutations that progressively transform them into a malignant state. Reaching this 
state is a multi-step process. Mutations leading to activation of growth promoting genes 
(oncogenes) or deactivation of growth suppressor (tumour suppressor) genes typically 
lead to cancer. Cancer cells develop mechanisms to avoid senescence, cell death signals 
and expression of tumour suppressors (Hanahan & Weinberg, 2011).. They often break 
out of normal tissue confines by increased migration and invasiveness. Cancer cells can 
induce the formation of blood vessels (angiogenesis, to derive their own nourishment) 
and sometimes new lymphatic vessels (lymphangiogenesis, which promotes lymphatic 
metastasis). These processes allow them to metastasize to other parts of the body 
(Hanahan & Weinberg, 2011). According to current statistics, one in nine Canadian 
women are expected to develop breast cancer over their lifetime and one in twenty-nine 
Canadian women will die from the disease (Canadian Cancer Society 2013). Breast 
cancer accounts for the second highest cancer-related mortality in females (Canadian 
Cancer Statistics).  
Normal breast architecture consists of multiple milk-making glands that form a cluster of 
lobules, which are connected to the nipple through interlobular ducts. The lobules and 
ducts are surrounded by a layer of luminal and myoepithelial cells, and are separated 
from surrounding tissue by a basement membrane. Breast cancer can be broken down 
into categories based on histology. The two common types of non-metastatic breast 
cancer are ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), which 
refer to cancers located in the milk ducts or milk-making glands. The tumour becomes 
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invasive when the cells break down the basement membrane and from there spread to 
surrounding breast tissue, and ultimately metastasize to other parts of the body.  
Breast cancer can also be classified based on the presence or absence of specific 
immunopathological markers. Treatment options and prognosis are often based on these 
markers. The markers are comprised of the estrogen receptor (ER), progesterone receptor 
(PR) and human epidermal receptor 2 (HER2) (Bertos & Park, 2011). The usual course of 
treatment for ER+ tumours is anti-estrogen endocrine therapy, while HER2+ tumours are 
linked with poorer prognosis and are usually treated with the HER2 inhibitor 
Trastuzumab (Herceptin) (Vuong, Simpson, Green, Cummings, & Lakhani, 2014).  
Breast cancer can be further classified according to mRNA transcription categories: 
luminal A, luminal B, basal, HER2 and claudin low. Luminal A subtypes have higher 
levels of Estrogen receptor 1 (ESR1) and ER regulated genes, lower ki-67 expression, a 
marker for cell proliferation, and better survival rates compared to the luminal B subtype. 
Claudin-low tumours are linked to poor outcomes, while the basal subtype is associated 
with ER-/PR-/HER2- or the triple negative cohort, the most severe form of breast cancer 
(Bertos & Park, 2011; Vuong et al., 2014). Despite these classifications, breast cancer 
tumours contain a heterogeneous population of cells, which makes them harder to treat. 
This heterogeneity might arise from a combination of mutations within cells and 
differentiation of mutated stem like cells (SLCs) during cancer (Reya, Morrison, Clarke, 
& Weissman, 2001). Traditional therapies are often unable to completely eradicate all 
cancer cells, leaving behind the SLC tumour cell subset, which leads to tumour 
reoccurrence. As such, there is a pressing need to identify novel drug targets and 
biomarkers for therapeutic monitoring. 
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1.2 Stem Like Cells 
SLCs are a rare population of cells within the tumour that possess certain stem cell like 
properties that drive the initiation and growth of tumours, and promote reoccurrence of 
cancer (Campbell & Polyak, 2014; Reya et al., 2001). Normal stem cells persist in the 
body through self-renewal properties, and are able to generate mature cells through 
differentiation (Reya et al., 2001). The cancer stem cell model suggests that SLCs could 
be derived from transformed stem cells, progenitor cells or differentiated cells (Reya et 
al., 2001). The genetic makeup of SLCs is continuously evolving, giving them treatment-
resistant properties that are passed down to daughter generations (Valent et al., 2012). 
Quiescent SLCs can evade traditional therapies such as radiation and chemotherapy, 
which target rapidly dividing cells that make up the bulk of the tumour population. This 
causes a reduction in tumour size but is not a complete cure due to SLCs that exist in a 
quiescent or dormant state (Kai, Arima, Kamiya, & Saya, 2010; Tysnes, 2010; Wicha, 
Liu, & Dontu, 2006). Recent evidence suggests that SLCs adopt a functional state 
dependent on extrinsic micro-environmental factors in the ―SLC-niche‖ (Visvader & 
Lindeman, 2012). For instance, in colorectal cancer, myofibroblasts secrete factors which 
are able to confer the stem cell phenotype in more differentiated tumour cells (Vermeulen 
et al., 2010).  
With advancements in technology, we are now able to address SLC properties in vitro. 
One such assay cultures undifferentiated cells in spherical colonies referred to as 
tumourspheres. These are grown under low-attachment (anchorage independent) 
conditions in serum free medium supplemented with growth factors (Dontu et al., 2003). 
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SLCs are also characterized by the presence or absence of cell surface markers and 
enzyme activities. Tumourspheres in breast cancer were found to be enriched primarily 
for undifferentiated cells and cells expressing surface markers CD44+/CD24- (Dontu et 
al., 2003; Ponti et al., 2005). Cancer cells sorted for CD44+/CD24- phenotype displayed 
increased tumourigenicity after injection into immune-compromised mice (Al-Hajj, 
Wicha, Benito-Hernandez, Morrison, & Clarke, 2003). Aldehyde dehydrogenase 
(ALDH) activity has also been associated with SLCs. ALDH is a cytoplasmic 
detoxification enzyme and is highly expressed in multiple progenitor cell lineages 
(Vasiliou & Nebert, 2005). CD44+/CD24-/ALDH
high
 and CD44+/CD133+/ALDH
high
 
cells demonstrated increased tumoursphere forming ability and lung metastasis following 
tail vein injection in immune-compromised mice (Croker et al., 2009). Interestingly, 
another study also found that high ALDH1 expression in DCIC breast biopsies is 
associated with increased risk of breast cancer development (Kunju et al., 2011). In 
addition, expression of pluripotency genes such as SOX-2, Nanog, OCT4 has also been 
associated with SLCs in various cancers including the breast (Chiou et al., 2010; Ezeh, 
Turek, Reijo, & Clark, 2005; Leis et al., 2012). Thus, SLCs may be prospectively 
identified in breast cancer by the CD44+/CD24-/CD133+/ALDH
high
 phenotype (Al-Hajj 
et al., 2003; Croker et al., 2009). Targeting these SLCs in breast cancer may reduce 
reoccurrence of cancer and improve patient survival. 
 
1.3 Epithelial to Mesenchymal Transition 
Epithelial to mesenchymal transition (EMT) is an important component of cancer 
metastasis. Cancer metastasis is a complex process which involves the generation of 
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motile tumour cells, breakdown and migration through the basement membrane and 
migration into blood or lymphatic vessels, extravasation to a secondary site and 
establishment of secondary tumours (Tsuji, Ibaragi, & Hu, 2009). At the sub-cellular 
level, loss of tight junctions, adherens junctions and desmosomes, is observed as well as 
cytoskeletal changes and differential expression of adhesion molecules and transcription 
factors. During EMT, decreased expression of CDH1 (E-Cadherin) is associated with loss 
of cell-cell contacts and epithelial cell polarity (Adams & Nelson, 1998; Vincent-
Salomon & Thiery, 2003). There is also a concurrent increase in expression of 
mesenchymal markers Twist1, Snail1 (Snail) and Zeb1 which are translational repressors 
of E-Cadherin (Peinado, Olmeda, & Cano, 2007). Changes in cells from highly organized 
epithelial like cells to a more motile mesenchymal cell are characteristics of cancer cell 
plasticity (Thiery, 2002). Identifying cells prone to EMT will help us target cells that are 
more likely to metastasize. 
 
1.4 Cyclo-oxygenase Enzymes and Prostanoids 
Over the past decade, our laboratory has pioneered the investigation into the role of 
cyclo-oxygenase (COX) system in cancer promotion (Dunn, Majumder, & Lala, 2014; 
Landman, Majumder, Liu, & Lala, 2014; Majumder, Xin, Liu, Girish, & Lala, 2014; 
Rozic, Chakraborty, & Lala, 2001; Timoshenko, Lala, & Chakraborty, 2004; Xin et al., 
2012).  Elevated COX-2 expression was observed in approximately 85% of human 
colorectal cancers and in 37.4% of breast cancer tumours compared to normal tissue 
(Eberhart et al., 1994; Ristimaki et al., 2002). Furthermore, high expression of COX-2 
has been demonstrated in hepatocellular carcinoma and lung cancer (Soslow et al., 2000; 
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Tang, 2005). Aberrant cyclo-oxygenase (COX)-2 up-regulation during chronic 
inflammation is believed to play a major role in carcinogenesis (FitzGerald, 2003). 
COX enzymes catalyze the rate limiting step in the formation of prostanoids. There are 
three isoforms of the enzyme, COX-1 and COX-2, and the lesser studied COX-3, which 
is a variant of COX-1 (Chandrasekharan et al., 2002). COX-1 is constitutively expressed 
in most tissues including the lungs, small and large intestine, liver, and kidney. It 
generates steady and low levels of prostanoids needed for physiological functions such as 
vaso-relaxation, platelet aggregation and protection of gastro-intestinal lining epithelia. In 
contrast, COX-2 expression is induced locally in multiple tissues by inflammatory 
cytokines and mitogens, producing high prostanoid levels required to combat pathogens 
through mobilization of leukocytes into interstitial space (FitzGerald, 2003). 
Production of prostanoids, in particular prostaglandin (PG)E2, depends mainly on COX-1 
and COX-2 expression. When stimulated, arachidonate is cleaved from the lipid bilayer 
by phospholipase-A2 (PLA2). Liberated arachidonic acid is then converted to 
prostaglandin (PG)H2 in a two step reaction via the COX enzymes. Through different 
cell-specific synthases, PGH2 is converted to signaling molecules, which include 
Prostacyclin (PGI2), Thromboxane A2, Prostaglandin D2, Prostaglandin F2α and 
Prostaglandin E2. These prostanoids subsequently mediate pleiotropic effects through 
multiple receptors. Notably, PGE2 was determined to be the most abundant prostaglandin 
released from breast cancer cells (Timoshenko, Xu, Chakrabarti, Lala, & Chakraborty, 
2003). PGE2 mediates its effects through four different G-protein-coupled receptors, EP1-
4.  
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EP1 activation is coupled with Gq and leads to increased intracellular calcium 
mobilization. In contrast, PGE2 signaling is mediated primarily by EP2 and EP4 receptors 
coupled with Gs, resulting in increased cyclic 3,5-adenosine monophosphate (cAMP), 
whereas EP3 stimulation is coupled with G protein Gi and  inhibits adenylate cyclase 
activity resulting in decreased (cAMP) levels (Bos, Richel, Ritsema, Peppelenbosch, & 
Versteeg, 2004). More recently, EP4 was also demonstrated to mediate its effects through 
the phosphatidylinositol 3-kinase (PI3K) pathway which phosphorylates extracellular 
signal-regulated kinases (ERKs) (Fujino & Regan, 2006; Fujino, Xu, & Regan, 2003). 
This pathway is unique to EP4 and not utilized by EP2.  Prostanoids mediate a complex 
array of signaling pathways essential to homeostatic function, on the other hand 
uncontrolled signaling has been implicated in cancer. 
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Figure 1. Cyclo-oxygenase enzymes, prostanoids and EP receptors 
COX-1 and COX-2 convert arachidonic acid into prostaglandin precursors PGG2 and 
PGH2 through a two step rate limiting reaction. PGH2 is converted to various prostanoids 
through different prostanoid synthases. Most notably, COX enzymes mediate the 
formation of PGE2, which has been associated with breast cancer aggressiveness. PGE2 
acts on four different EP receptors. Our lab is investigating COX-2 mediated breast 
cancer progression, focusing on the pathway highlighted in red. 
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1.5 COX Inhibitors 
Non-selective COX-1/COX-2 inhibitors are non-steroidal anti-inflammatory drugs 
(NSAIDs) with Aspirin-like properties, and primarily utilized for analgesic, anti-
inflammatory and fever reducing activities (Flower, 2003). In the 1970s, Aspirin and 
Aspirin-like-drugs were shown to reduce prostaglandin levels in humans (Smith & Willis, 
1971). Interestingly, these drugs also showed promise as anti-cancer agents. For instance, 
patients treated with low-dose Aspirin had a decrease in fatal colon cancer (Thun, 
Namboodiri, & Heath, 1991). However, chronic use of NSAIDs is associated with 
adverse effects such as gastric intolerance and delay of blood clotting. Selective COX-2 
inhibitors, such as Celecoxib (Celebrex, Pfizer), have shown promising therapeutic 
effects and chemoprotective effects in a variety of cancers (Harris, 2009). The use of 
COX-2 inhibitors has exhibited increased apoptosis in head and neck carcinoma, reduced 
tumour formation in colon cancer and breast cancer (Harris, Alshafie, Abou-Issa, & 
Seibert, 2000; Kim et al., 2010; Sheng et al., 1997). However, prolonged use of COX-1 
and COX-2 inhibitors has been associated with adverse cardiovascular events such as 
myocardial infarction, cardiac arrest, stroke and pulmonary embolisms in a small subset 
of patients (Fitzgerald, 2004; Graham, 2006; Nussmeier et al., 2005). The increased 
incidence of cardiovascular events is believed to result from the inhibition of cardio-
protective prostanoids such as PGI2; which blocks platelet aggregation and promotes 
vaso-dilation (Fitzgerald, 2004). COX-2 inhibitors disrupt the balance of PGI2 and 
thromboxane A2 present in the body (Fitzgerald, 2004). Thromboxane A2 plays a role in 
vasoconstriction and platelet aggregation, and is mainly produced by COX-1 thus 
generally unaffected by selective COX-2 inhibitors. Because PGE2 signals through EP4 
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via a unique pathway not shared by other EPs, our lab is investigating the receptor as 
more selective down-stream target of COX-2 activity that avoids cardiovascular side-
effects observed with prolonged use of COX-2 inhibitors.  
 
1.6 COX-2 and Breast Cancer 
COX-2 has an important role in breast cancer progression. In tumours, COX-2 expression 
has been correlated with negative hormone receptor (ER and PR) status and HER2 
amplification (Ristimaki et al., 2002) (Majumder et al. submitted Oncogene). 
Furthermore, studies in our laboratory have demonstrated that ectopically expressed 
COX-2 in breast cancer cell lines increase cell migration, invasion and proliferation 
(Majumder et al. submitted Oncogene). Increased proliferation is also a characteristic of 
COX-2 high tumours (Ristimaki et al., 2002).  In breast cancer tissue, high COX-2 has 
been associated with matrix metalloproteinase (MMP)-2 activation, which degrade 
components in the extracellular matrix and the basement membrane (Sivula et al., 2005). 
Furthermore, high COX-2 expression is associated with high VEGF-C and LYVE-1, 
markers for endothelial lymphatic cells (Timoshenko, Chakraborty, Wagner, & Lala, 
2006), and COX-2 over-expression  demonstrated up-regulated production of angiogenic 
(VEGF-A) and lymphangiogenic (VEGF-C and –D) factors (Timoshenko et al., 2006) 
(Majumder et al. submitted Oncogene). Furthermore, COX-2 transfection markedly 
increased the size and frequency of clonogenic spheroid formation (a surrogate of SLC 
function in vitro) (Majumder et al. submitted Oncogene). Tumourspheres formed from 
COX-2 over-expressing cells had increased co-expression of the breast cancer stem cell 
markers CD44 and ALDH, as well as embryonic stem cell pluripotency markers SOX-2 
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and OCT-3/4 (Majumder, Xin, Liu, Girish, et al., 2014) (Majumder et al. submitted 
Oncogene). EMT phenotype was observed in COX-2 over-expressing breast cancer cells, 
shown by decreased expression of epithelial marker CDH1 and increased expression of 
mesenchymal markers VIM (Vimentin), Twist1 and CDH2 (N-Cadherin) (Majumder, 
Landman, Liu, Hess, & Lala, 2015) (Majumder et al. submitted Oncogene). Finally, 
COX-2 over-expressing cells demonstrated a marked increase in lung colony forming 
ability and orthotopic tumourigenicity after serial transplantation into immunodeficient 
murine recipients (Majumder et al. 2014). Collectively, these observations are consistent 
with increased metastasis and reduced survival in breast cancer patients with high COX-2 
expression within tumours (Ristimaki et al., 2002). 
 
1.7 PGE2 and Breast Cancer 
As mentioned previously, PGE2 is the main prostainoid resulting from increased COX-2 
activity in breast cancer cells (Timoshenko et al., 2003). Our lab has shown that PGE2 
promotes tumour progression and metastasis by multiple mechanisms; (1) including the 
inactivation of cancer-fighting immune cells (Lala, Santer, Libenson, & Parhar, 1985; 
Parhar & Lala, 1985), (2) stimulation of cancer cell migration (Rozic et al., 2001; 
Timoshenko et al., 2003) and invasion (Timoshenko et al., 2004), (3) cancer-associated 
angiogenesis (Rozic et al., 2001), and (4) lymphangiogenesis by up-regulation of VEGF-
C or VEGF-D (Timoshenko et al., 2006; Xin et al., 2012). Therefore, COX-2 mediated 
production of PGE2 promotes cancer associated functions. 
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1.8 COX-2 induced miRNAs in breast cancer 
MicroRNAs (miRNAs) are small regulatory RNA molecules (19-24 nucleotides) that are 
transcribed from DNA but not translated into protein. miRNAs act to down-regulate gene 
expression at the post-transcriptional level by either degrading mRNA of their target gene 
or by blocking translation of the target gene into protein. They recognize their target gene 
through sequence complementarity, usually located on the target gene‘s 3‘untranslated 
region (UTR) (Sassen, Miska, & Caldas, 2008). MiRNA biogenesis starts with RNA 
polymerase II or III driven generation of pri-miRNA strands. Drosha RNase III 
endonuclease performs nuclear cleavage of the the pri-miRNA strand, generating a stem 
loop structure intermediate or the miRNA precursor (pre-miRNA). The pre-miRNA is 
then transported to the cytoplasm by Ran-GTP and Exportin-5. Next, Dicer cleaves the 
pre-miRNA, removing the loop and terminal base pairs. This produces the mature 
miRNA and a similar sized complementary fragment referred to as the miRNA*. The 
miRNA:miRNA* duplex is short lived and the miRNA* is subsequently degraded. The 
mature miRNA is incorporated into the RNA-induced silencing complex (RISC), which 
then suppresses target gene expression (Bartel, 2004). MiRNAs have been associated 
with oncogenic and anti-oncogenic (tumour-suppressor-like) functions.  Interestingly, 
miRNAs can be found in body fluids within micro-vesicles (Kosaka, Iguchi, & Ochiya, 
2010). Therefore, expression of certain miRNAs can be utilized as potential cancer 
biomarkers (Calin & Croce, 2006). 
Affymetrix microRNA micro-array comparison of the MCF7-COX-2 cells and MCF7-
Mock cells, identified two miRNAs, miR-526b and miR-655, that are up-regulated in the 
COX-2 over-expressing cell lines. COX-2 low breast cancer cells treated with PGE2 or 
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EP4 agonists had higher expression of miR-526b and miR-655 (Majumder et al., 2015) 
Furthermore, COX-2 over-expressing tumourspheres demonstrated higher expression of 
these miRNAs, suggesting that these miRNAs are COX-2 and EP4 induced (Dunn et al., 
2014; Majumder, Postovit, et al., 2014). MiR-526b and miR-655 over-expressing cells 
also showed increased migration, invasion, proliferation and tumoursphere formation 
(Dunn et al., 2014; Majumder et al., 2015). When these miRNA over-expressing cells 
were treated with EP4 antagonists, a reduction in spheroid formation was observed.  In 
vivo studies of these miRNA over-expressing breast cancer cells revealed an increase in 
proliferative lung colonies in mice compared to MCF7-Mock cells (Majumder et al., 
2015; Majumder, Xin, Liu, Bell, et al., 2014). In situ studies demonstrate that both miR-
526b and miR-655 are higher in breast cancer tissue and are negatively correlated with 
patient survival (Majumder et al., 2015; Majumder, Postovit, et al., 2014). Therefore, 
miR-526b and miR-655 are considered oncogenic with SLC-inducing properties which 
are mediated through COX-2 and EP4. Interestingly, cytoplasmic polyadenylation 
element binding protein (CPEB)-2 is the common gene target for both miRNAs. By 
extension, we propose that CPEB2 may demonstrate anti-oncogenic properties, and 
down-regulation of CPEB-2 by miR-526b and miR-655 promotes breast cancer 
aggressiveness. 
 
1.9 The CPEB Family of Proteins 
Translation of eukaryotic mRNAs can be regulated through the length of their poly(A) 
tails (Macdonald, 2001). CPEB1, the founding member of the CPEB family, was first 
described to play a role in oocyte maturation (Hake & Richter, 1994). CPEB1 regulates 
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translation by associating with specific sequences in the 3‘ UTR of their target mRNA 
called cytoplasmic polyadenylation elements (CPEs, sequence: UUUUUAU) 
(D‘Ambrogio, Nagaoka, & Richter, 2013; Hake, Mendez, & Richter, 1998). All CPEBs 
have some common structural elements including an N-terminal regulatory domain and a 
C-terminal RNA-binding domain. The RNA-binding domain contains two RNA 
recognition motifs (RRMs) and a cysteine-histidine zinc finger region, which when 
deleted impair the ability of CPEBs to bind to target mRNAs (Hake et al., 1998). Based 
on amino acid homologies in the coding regions and RNA binding regions (RRMs and 
zing finger regions), human CPEBs can be divided into two subfamilies: CPEB1 and 
CPEB2-4 (Huang, Kan, Lin, & Richter, 2006; Kurihara et al., 2003).  The RNA binding 
domains of CPEB2, CPEB3 and CPEB4 are very similar, suggesting that they might 
share similar recognition sequences (Kurihara et al., 2003). 
Unlike CPEB1, CPEB3 and CPEB4 do not interact with CPEs and bind other RNA 
binding sequences (Huang et al., 2006). Furthermore, unlike CPEB1, CPEB3 does not 
bind the cleavage and polyadenylation specificity factor (CPSF) (Huang et al., 2006). 
This suggests that CPEB3 and CPEB4 do not regulate translation through 
polyadenylation and do so through an independent mechanism. Although little is known 
on CPEB2 function, it is postulated that since CPEB2 is more similar to CPEB3-4 than 
CPEB1, then CPEB2 RNA binding sequences should be similar to CPEB3-4 and not 
CPEB1. However, a more recent paper highlights that both CPEB1 and CPEB2 bind to 
the CPE in HIF-1α RNA, to regulate its protein expression (Hägele, Kühn, Böning, & 
Katschinski, 2009). This suggests that CPEB2 regulates translation through 
polyadenylation and possibly another mechanism similar to CPEB3-4. 
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CPEB1 has been associated with cellular senescence, loss of polarity and suppression of 
malignancy (D‘Ambrogio et al., 2013). CPEB1 knock-out mouse embryonic fibroblast 
cells avoid senescence and continue to divide (Groisman et al., 2006). When CPEB1 is 
re-introduced into CPEB1 low cells, cell stop dividing and express senescence associated 
marker β-galactosidase (Burns & Richter, 2008; Groisman et al., 2006). CPEB1 has also 
been shown to play a role in synaptic plasticity by regulating the translation 
α‐Ca2+/calmodulin‐dependent protein kinase II (αCaMKII) mRNA (Huang, Jung, 
Sarkissian, & Richter, 2002; Wu et al., 1998). Meta-analysis of global gene expression in 
cancers compared to normal tissues has shown that CPEB1 mRNA is lower in brain and 
reproductive system cancer, and CPEB3 mRNA is lower in digestive tract cancer, brain 
tumours and, head and neck tumour (D‘Ambrogio et al., 2013). On the other hand, 
CPEB4 mRNA is higher in pancreatic glioblastomas (D‘Ambrogio et al., 2013). 
 
1.9.1 CPEB2  
In mouse organs, CPEB2 RNA has been detected in large quantities in the testis, and is 
also found at lower levels in the brain, liver, thymus, salivary glands, spleen, kidney, 
intestines and ovaries (Chen & Huang, 2012; Kurihara et al., 2003). The amount of 
CPEB2 in breast tissue has not been investigated. HeLa cells transfected with a CPEB2-
GFP construct demonstrated that the protein is localized in the cytoplasm in cells (Huang 
et al., 2002; Kurihara et al., 2003). The role of CPEB2 in breast cancer has not been 
studied, but it may represent an important therapeutic target for cancer therapy due to its 
known targets. 
17 
 
1.9.2 CPEB2 Targets 
Genes involved in antioxidant defence systems, such as hypoxia inducible factor (HIF)-
1α, are up-regulated in breast cancer stem cells (Kai et al., 2010). HIF-1α over-expression 
in cancer has been associated with increased patient mortality in cancers of the brain, 
breast, cervix, oropharynx, ovary, and uterus (Semenza, 2003). HIF-1α has been shown 
to up-regulate genes involved in apoptosis resistance, angiogenesis and metastasis 
(Semenza, 2003). Under normoxic conditions, CPEB2 interacts with eukaryotic 
elongation factor (eEF)-2 and binds to the 3‘UTR of HIF-1α, reducing HIF-1α peptide 
elongation (Chen & Huang, 2012). Under arsenite induced stress, CPEB2 is released 
from HIF-1α RNA and no longer interacts with eEF2. This allows eEF2 to resume 
maximum GTPase activity and increases the translation of HIF-1α (Chen & Huang, 2012; 
Hägele et al., 2009), leading to up-regulation of hypoxia induced factors such as VEGF. 
Nairismägi et al. (2012) have shown that CPEB2 also has a role in the post-
transcriptional regulation of Twist1, a gene involved in the EMT transition. Using 
immuno-precipitation, the authors determined that CPEB2 associates with Twist1 mRNA 
and over-expressing CPEB2 leads to decreased Twist1 protein levels (Nairismägi et al., 
2012). Recently, β-catenin,  CaMKIIα, and ephrin receptor A4 (EphA4) have been 
identified as CPEB2 targets in mouse brain (Turimella et al., 2015). β-catenin and 
CaMKIIα are also established CPEB1 targets (Hägele et al., 2009; Wu et al., 1998). This 
shows that there is an overlap of target molecules between CPEB1 and CPEB2. 
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1.9.3 MiRNAs and CPEB2 
CPEB2, along with CPEB3-4, have previously been shown to be negatively regulated by 
miR-92 and miR-26. Both these miRNAs bind to the predicted recognition motif in the 3‘ 
UTR of CPEB2-4 and reduce transcript levels (Morgan, Iaconcig, & Muro, 2010). MiR-
92 is up-regulated in certain human cancers, is associated with increased proliferation and 
reduced apoptosis, and is inversely correlated with estrogen receptor β1 (Erβ1) in breast 
cancer cell lines (Al-Nakhle et al., 2010; Manni et al., 2009; Shigoka et al., 2010; 
Tsuchida et al., 2011; Ventura et al., 2008). On the other hand, miR-26 has both 
oncogenic and tumour suppressive roles, where it has high expression in high grade 
glioma cells and reduced expression in breast cancer tumour tissues (Huse et al., 2009; 
Zhang et al., 2011).  
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1.10 Rationale 
Our laboratory has previously shown that COX-2 promotes aggressive properties and 
induces a SLC phenotype in breast cancer cells; and that these functions are at least in 
part mediated by PGE2, EP4 and COX-2-induced miR-526b and miR-655. Stable 
transfection of COX-2 into human breast cancer cell lines MCF7 (COX-2 low, ER+, 
HER2–) and SKBR3 (COX-2 low, ER–, HER2+), induced all the phenotypic properties 
of aggressive breast cancer in vitro and in vivo (Majumder, Postovit, et al., 2014). 
Therefore, a combined Affymetrix gene expression and microRNA analysis of the COX-
2 transfected cells compared to the mock transfected cells was performed. Out of the 848 
microRNAs tested, only two were up-regulated by COX-2 transfection, miR-526b and 
miR-655. At the same time, out of 28,870 genes tested only 26 were down-regulated with 
COX-2 transfection. Interestingly, out of the 26 down-regulated genes, either miR-655 or 
miR-526b targeted 13 genes identified through the micro-array. The only common gene 
target of both miR-655 and miR-526b was CPEB2. Since both oncogenic miR-655 and 
miR-526b have target sites of the 3‘ untranslated region (UTR) of CPEB2, and miRNAs 
down-regulate specific gene expression, we postulate that CPEB2 might have an anti-
oncogenic role in breast cancer. 
Since microRNAs are stable in patient‘s serum, these oncogenic miRNAs can serve as 
potential markers for screening of SLCs and therapeutic responses in the clinic. 
Furthermore, gene expression profiles can be important prognostic markers in cancer. 
Thus, establishing a tumour-suppressor-like role for the CPEB2 will allow us to identify 
CPEB2 as a novel therapeutic target for tumour suppression in breast cancer. 
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1.11 Central Hypothesis: 
Down-regulation of CPEB2 promotes an aggressive breast cancer phenotype through 
SLC induction and EMT. 
 
Specific Aims 
1) To investigate if there is an inverse relationship between expression levels of a) 
CPEB2 and COX-2 and b) CPEB2 and miR-655 or miR-526b in human breast 
cancer cell lines. 
2) To elucidate the effects of CPEB2 knock-down on MCF7 cell migration, 
invasion, proliferation, SLC function, and EMT in vitro 
3) To investigate the effects of COX-2 inhibitor, and PGE2 (EP1-4 ligand), EP4 
agonist and antagonist treatments on CPEB2 levels. 
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2 EXPERIMENTAL METHODS 
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2.1 Cell Culture 
The breast cancer cell lines used in this project are summarized in Table 1. All cells were 
purchased from the American Type Culture Collection (ATCC). MCF7 cells were 
extensively used in this thesis. MCF7 cells originated from the mammary gland of a 
patient with adenocarcinoma (ATCC, 2015). These cells are ER and PR positive, and 
HER2 negative (Kao et al., 2009). Furthermore, MCF7 cells are low in COX-2 
(Majumder, Postovit, et al., 2014) and high in CPEB2, making them ideal candidates for 
CPEB2 knockdown in this study.  
All breast cancer cell lines were maintained as monolayers in T-75 cm
2
 flasks (Falcon) in 
a humidified incubator with 5% CO2 at 37°C. MCF7 cells were grown in Eagle‘s 
Minimum Essential Media (EMEM, ATCC) supplemented with 10% Fetal Bovine Serum 
(FBS, Gibco), 100 µg/mL of penicillin/streptomycin (pen/strep, Gibco) and 10 µg/mL of 
insulin (Sigma). SKBR3 cells were grown in McCoy‘s 5A Modified Media (Gibco), and 
MDAMB231, HS578T and T47D cells were grown in RPMI-1640 Media (Gibco) 
supplemented with 10% FBS and 100 µg/mL pen/strep. Cells were washed with DPBS 
(Gibco) and media was changed every 48 hours. Cells were detached with 0.25% Trypsin 
(Gibco) and re-plated, as required.  
 
2.2 COX-2, CPEB2, miR-655 and miR-526b status in breast cancer cell lines 
To determine the status of COX-2 and CPEB2 expression, miR-655 and miR-526b in 
different breast cancer cell lines, real-time PCR was performed using the TaqMan gene 
expression assay as described in ‗2.5‘. 
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2.3 MCF7 Cell Transfection 
Over-expression of COX-2 was achieved using a pCMV-IRES2-EGFP-COX-2 vector 
which contained a cytomegalovirus (CMV) promoter. The plasmid also contains an 
enhanced green fluorescence protein (EGFP) and neomycin resistance genes which can 
be used to sort transfected cells. 
Dr. Mousumi Majumder previously transfected MCF7 cells with 2 µg of either pCMV-
IRES-EGFP (control) plasmid or pCMV-IRES2-EGFP-COX-2 over-expression plasmid 
(Dr. Michael Archer, University of Toronto). The resulting cell line was named MCF7-
COX-2. COX-2 over-expression was validated with real-time PCR as described in ‗2.5‘. 
Media was supplemented with 500 µg/mL of Geneticin® (Gibco) to maintain selective 
pressure.  
 
2.4 Nucleofection 
Electroporation is a transfection method that involves the application of short electronic 
pulses to cells, which increase their permeability to macromolecules (Iversen, Birkenes, 
Torsdalen, & Djurovic, 2005). To increase transfection efficiency, nucleofection was 
employed. Nucleofection involves cell-specific delivery systems (nucleofector solution) 
and electronic pulses to optimize delivery of DNA, small-interfering RNA (siRNA) 
oligonucleotides to the nucleus of cells (Han et al., 2008). Nucleofection was performed 
using the Amaxa Biosystems Nucleofector® 2 system, the Cell Line Nucleofector® Kit 
V (Lonza) and associated protocol. The nucleofection protocol was validated by 
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transfecting MCF7 cells with the supplied pmaxGFP Vector® (Lonza). Expression of 
GFP was confirmed by fluorescence microscopy in MCF7 cells. 
 
2.4.1 CPEB2 knockdown with siRNAs 
In vitro CPEB2 knockdown was achieved using siRNAs. Similar to miRNAs, siRNAs 
bind and degrade target genes with complementary mRNA sequences through RISC 
(Carthew & Sontheimer, 2009). For this project, siRNAs were transfected into MCF7 
cells to down-regulate CPEB2 expression. Parental MCF7 (COX-2 low) human breast 
cancer cell line expressed high levels of CPEB2. MCF7 cells were grown until 80% 
confluent in T-75 cm
2
 flasks (Falcon). Cells were trypsinized and pelleted. Two million 
cells were transferred into certified cuvettes along with supplemented nucleofector® 
solution (Lonza) and 1 µM of either CPEB2 siRNA (OriGene) or Universal Scrambled 
Control siRNA ([Control siRNA], OriGene). The program used for transfection was P-
020. After nucleofection, cells were incubated at 37°C and 5% CO2 in appropriate 
antibiotic free media. After 24 hours media was changed and experiments were 
conducted after 48 hours. The resulting cell lines were named MCF7-Scrambled and 
MCF7-CPEB2 KD. CPEB2 KD was validated using RT-PCR. To look at the functional 
role of CPEB2, the following assays were tested: migration (Transwell assay), invasion 
(Matrigel Transwell Assay), proliferation (BrdU uptake), EMT phenotype (real-time 
PCR/IF) and in vitro SLC content (clonogenic tumoursphere formation on ultra-low 
attachment plates/IF).  
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2.5 Quantification of CPEB2 knockdown with polymerase chain reaction (RT-PCR) 
Real-time polymerase chain reaction (real-time PCR) was used to quantify the amount of 
specific mRNA transcripts present in a sample using fluorescent technology. We used a 
multi-step protocol that involves: (1) RNA purification, (2) conversion of RNA into 
cDNA, and (3) detection of PCR product (Fraga, Meulia, & Fenster, 2008). In general, 
the less time it takes for an amplified target sequence to pass the detection threshold, the 
greater the amount of target sequence there is in the starting material (Fraga et al., 2008). 
Cells were grown until 80-90% confluent, after which they were trypsinized and pelleted. 
Total RNA and miRNA was extracted using RNeasy Minikit and RNeasy MiniElute 
Cleanup Kit (Qiagen) by following manufacture‘s protocol (Qiagen, 2010a, 2010b). Total 
RNA and miRNA concentration was quantified using the Epoch Microplate 
Spectrophotometer (BioTek®).  
RNA and miRNA was converted into cDNA using a RNA-dependent DNA polymerase 
(Reverse Transcriptase). cDNA was synthesized using reagents from the High Capacity 
cDNA Reverse Transcription Kit and TaqMan MicroRNA Reverse Transcription Kit 
(Life Technologies). In the case of RNA synthesis, random primers were used, while for 
miRNA synthesis 3 µL of specific primers for miR-526b, miR-655, RNU44 and RNU48 
(Life Technologies) were used. For each sample, 1 µg of RNA per 20 µL reaction or 0.5 
µg of miRNA per 28 µL reaction were used to synthesize cDNA using the C1000™ 
Thermal Cycler (BioRad). The following parameters were used to perform reverse 
transcription from RNA: hold for 10 min at 25°C, 120 min at 37°C, 5 min at 85°C, then 
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hold at 4°C; and from miRNA: hold for 30 min at 16°C, 30 min at 42°C, 5 min at 85°C, 
then hold at 4°C.  
For accurate detection of PCR product, PCR mixture was made using reagents from the 
TaqMan Universal PCR Master Mix (RNA) and TaqMan Universal PCR Master Mix, no 
AmpErase UNG kit (miRNA, Life Technologies). Each qPCR reaction tube was prepared 
to a volume of 20 µL with 1 µL of appropriate TaqMan Probe, and 2 µL of cDNA. The 
probes that were used in this experiment are listed in Table 2. House-keeping genes β-
actin and RPL5 (for RNA), and RNU44 and RNU48 (for miRNA) were used as controls. 
The real-time PCR was performed on the Rotor-Gene 3000 (Corbett Research), using the 
profile: hold for 2 min at 50°C, 10 min at 95°C followed by 45x cycling with denaturing 
15 sec at 95°C, and anneal/extension cycles for 1 min at 58°C. 
Data was analysed using the relative quantification method (2
-ΔΔCT
), where change in 
expression of a target gene from a treated or transfected group was compared to a control 
group (Livak & Schmittgen, 2001). 
 
2.6 Transwell Assay 
2.6.1 Migration Assay 
MCF7-Parental cells, MCF7-Scrambled, and MCF7-CPEB2 KD were grown until 80% 
confluent. Cells were serum starved in basal EMEM media overnight. A 24-well cell 
culture plate fitted with 8 µm microporous polycarbonate cell culture inserts (Fisher 
Scientific) was used to measure migration. The upper chamber contained 300 µL of cell 
suspension (2 x 10
5
 serum starved cells/mL of basal EMEM), while the bottom contained 
27 
 
700 µL of EMEM media with no FBS or 5% FBS. Both sides of the insert membranes 
were cell culture pre-treated to promote membrane cell-adherence and limit cell-growth 
on the walls of the insert. Cells that adhered to the bottom surface of the membrane 
inserts were counted as migratory cells.  
Previous work in the laboratory has shown that peak migration occurs at 24 hours (Rozic 
et al., 2001). Therefore, plates were incubated at 37°C and 5% CO2 for 24 hours after 
which membrane inserts were removed and the top of the membrane inserts were wiped 
carefully with a cotton swab to remove non-migratory cells. The membranes were fixed 
with cold 100% methanol and stained with Eosin and Thiasine (VWR), which stains the 
cytoplasm pink and nucleus purple. The membrane was then carefully removed from the 
inserts and mounted onto microscope slides. Cells from the whole insert were counted 
under a light microscope (Leica-DFC295). 
 
2.6.2 Invasion Assay (Matrigel) 
Another characteristic of the tumour cell metastatic phenotype is proteolytic activity that 
degrades the extracellular matrix (ECM) barrier (L. M. Shaw, 2005). Once cells have 
breached this barrier they can access the vasculature and lymphatic system (L. M. Shaw, 
2005). The protocol for this experiment is similar to ―2.6.1 Transwell Migration Assay‖, 
except that the upper section of the micro-porous polycarbonate membranes were coated 
with a Matrigel gelatinous protein mixture, which mimics the basement membrane. 
Matrigel is isolated from Englebreth-Holm-Swarm mouse sarcoma, and contains a 
mixture of basement membrane ECM proteins such as laminins, collagen IV, and 
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enactins (Hughes, Postovit, & Lajoie, 2010). The mixture was prepared by mixing 
Growth Factor Reduced Matrigel® (VWR) in 1:100 dilution with cold EMEM. Then, 
100 µL of diluted Matrigel was transferred onto the microporous polycarbonate 
membranes and left overnight to polymerize at room temperature. Before plating the 
cells, the matrigel layer was re-constituted with warm media for 30 mins at 37°C. Three 
hundred microliters of cell suspension (2 x 10
5
 serum starved cells/mL of basal EMEM) 
was transferred to the upper well. As previously described, 700 µL of media (no FBS or 
5% FBS) was transferred to the bottom well. Cells were incubated for 48 hours, which 
was time period that showed the highest invasion as determined by previous work in the 
laboratory (Rozic et al., 2001).  Membranes were fixed, stained and invading cells were 
counted. 
 
2.7 Bromodeoxyuridine (BrdU) Assay and Enzyme-Linked Immunosorbent Assay 
(ELISA) 
Cellular proliferation requires the synthesis of new DNA. The Bromo-deoxyuridine 
(BrdU) assay measures the incorporation of BrdU into newly synthesizing DNA. BrdU is 
a pyrimidine analogue and is able to base pair with adenine during DNA replication. The 
incorporation of BrdU is used as a measure of cell proliferation (Porstmann, Ternynck, & 
Avrameas, 1985).  
BrdU incorporation was detected using the Cell Proliferation ELISA, BrdU (colorimetric) 
Kit (Roche) following manufacture‘s protocol (Roche, 2010). Cells (100 µL at 104 
cells/mL) were transferred into a 96-well tissue culture microplate and incubated at 5% 
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CO2 and 37°C for 24 hours. Ten microliters of 100 µM BrdU was added to the cells and 
the cells were re-incubated at 37°C for 6 h. The labeling medium was removed and 200 
µL of FixDenat solution was added to fix cells for 30 min at room temperature. The 
solution was removed and 100 µL of anti-BrdU POD working solution was added to each 
well for 90 min. The anti-BrdU-POD binds to the BrdU in the denatured newly 
synthesized DNA. Following incubation, wells were washed three times with 200 µL of 
washing solution (1x PBS), after which 100 uL of substrate solution was added per well 
for 30 min. BrdU incorporation was quantified using an Epoch Microplate 
Spectrophotometer at a wavelength of 370 nm with a reference wavelength of 492 nm. 
 
2.8 Tumoursphere Formation Assays 
Non-adherent tumourspheres can be clonally derived from cells with stem cell properties 
(Dontu et al., 2003). MCF7 cells were grown until 80% confluent, trypsinized and re-
suspended in HuMEC media (Life Technologies) supplemented with epidermal growth 
factor (EGF, 20 ng/mL), fibroblast growth factor basic (FGFb, 20 ng/mL) and B-27® 
Supplement (1X, Invitrogen). To ensure that cells are plated as single cells, the solution 
was passed through a 27 ½ G needle (BD) and a 40 µM strainer (Falcon).  Five cells per 
well were plated into 96-well ultra-low attachment plates (Corning) for 7 days or until 
tumourspheres reached a size of at least 60 µm in diameter (F. L. Shaw et al., 2012). 
Spheroids were counted and photomicrographs were taken using a light microscope 
(Leica-DFC295). Spheroid formation efficiency  was also 
calculated. 
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2.9 Cell Staining for Immuno-fluorescence Microscopy 
2.9.1 Adherent cells 
MCF7-Parental, MCF7-Scrambled, and MCF7-CPEB2 KD cells were grown until 80%, 
harvested with trypsin, and 4 x 10
4
 cells were plated on cover-slips. After 24 hours cells 
were rinsed with PBS. To fix the cells, covers-slips were immersed in 4% para-
formaldehyde solution (Electron Microscopy Sciences) at room temperature for 30 min, 
and rinsed with PBS three times. For cell permeabilization, 0.5% Triton-X100 (J T Baker 
Chemical Co.) in PBS was added for 10 min at room temperature, followed by three 
times PBS wash. Cells were blocked in 4% BSA in PBS with 0.01% Tween® 20 (Sigma) 
for 30 min. After rinsing with PBS, cells were incubated with primary antibody (Table 3) 
in 4% BSA in PBS at 4°C overnight. If the primary antibody was conjugated to a 
fluorochrome, incubation with secondary antibody was not necessary. If not, the slides 
were rinsed with PBS and incubated with secondary antibody in 4% BSA in PBS for an 
hour. Twenty microliters of VECTASHIELD® Mounting Medium with DAPI (Vector 
Laboratories) was added on to the cover-slip and transferred onto a slide. The following 
primary antibodies were tested: E-Cadherin, Twist1, Nanog and ALDH1. 
Fluorescence intensities for Twist1 and E-Cadherin were calculated using ImageJ 
software. The raw integrated density was calculated for each cell and normalized to the 
cell area. Data were presented as an average of all the cells.  
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2.9.2 Non-adherent cells (Tumourspheres) 
Cells were grown until 80% confluent, trypsinized and re-suspended in supplemented 
HuMEC media following protocol outlined in tumoursphere formation assay. Ten 
thousand cells per mL cells were plated in 6-well non adherent cell culture plates for 5 
days or until the tumourspheres reach a size of 60 µm in diameter. After which, the 
tumourspheres and media were transferred into a 1.5 mL Eppendorf tube and left on the 
bench for 15 min to allow the tumourspheres to settle to the bottom. Media was carefully 
removed by manual pipetting and the tip of the pipette was cut to maintain spheroid 
structure. The fixation, permeabilization, and anti-body staining for non-adherent cells 
were identical to the protocol described previously for adherent cells. The only exception 
is that tumourspheres were allowed to settle for 1-2 min between PBS rinses to minimize 
loss. The following primary antibodies were tested: ALDH1, SOX-2, and Nanog. 
Quantification of fluorescence for ALDH1, Nanog, and SOX-2 were presented as ratio of 
cells with positive staining to the total number of cells marked by DAPI. 
 
2.10 COX-2 inhibitors, PGE2, EP4 Antagonists and Agonist Experiments 
MCF7-COX-2 (5x10
4
) cells were plated onto 6-well plates. Cells were serum starved 
overnight, after which they were washed with PBS and incubated for 24 hours with 
Celecoxib (10 or 20 µM), ONO-AE3-208 (10 or 20 µm) or vehicle control (0.003% 
DMSO). Celecoxib is a selective COX-2 inhibitor while ONO-AE3-208 is a selective 
EP4 antagonist.  
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To address the effect of PGE2 activity and EP4 signaling, MCF7 (5x10
4
) cells were 
plated onto 6-well plates. Cells were serum starved overnight, washed with PBS and 
incubated for 24 hours with PGE2 (10 µM) or PGE1OH (10 µm) or vehicle control 
(EtOH). PGE2 is a natural ligand for all EP receptors, while PGE1OH acts as a selective 
agonist for EP4. 
For all treated cells, RNA and miRNA was extracted as previously described, converted 
to cDNA and real-time PCR was performed to quantify the expression of CPEB2. 
 
2.11 Statistical Analysis: 
Statistical analyses were performed using GraphPad Prism Software Version 5.01 
(GraphPad Software Inc 2007). Data compared non-transfected, Scrambled and CPEB2-
KD cell lines using one-way ANOVA followed by Tukey‘s post hoc test or Scrambled 
and CPEB2-KD cells using unpaired students t-test. Results were considered statistically 
significant if p<0.05. 
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3 RESULTS 
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3.1 Inverse relationship of CPEB2 with COX-2, miR-655 and miR-526b expression 
Differential gene and miRNA microarray analysis of MCF7 breast cancer cells stably 
transfected with COX-2 over-expressing plasmid revealed down-regulation of 26 genes 
and up-regulation of two miRNAs. These two miRNAs, miR-655 and miR-526b, have 
been found to be oncogenic by our lab (Dunn et al., 2014; Majumder et al., 2015). 
Furthermore, their expression has been positively correlated with COX-2 expression. Out 
of the 26 genes suppressed by COX-2 expression, thirteen are targeted by either miR-655 
or miR-526b, with CPEB2 the only putative gene target of both miRNAs. Expression of 
COX-2, miR-655, miR-526b and CPEB2 was quantified in different breast cancer cell 
lines. Cell lines with high COX-2 and miRNAs expression, showed low expression of 
CPEB2 (Figure 2), reinforcing the inverse relationship suggested by the differential gene 
and miRNA microarray analyses previously performed (Majumder et al., 2015). 
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Figure 2. Breast cancer cell lines with high COX-2, and miR-655 and miR-526b 
expression demonstrate low CPEB2 expression  
A. We hypothesized that cells with high COX-2 have increased expression of oncogenic 
miR-655 and miR-526b, and low expression of CPEB2. B. RNA and miRNA was 
extracted from 4 distinct breast cancer cell lines with disparate COX-2 expression. Data 
are presented as average fold change normalized to MCF7-Parental (2
-ΔΔCT) ± SEM. β-
Actin and RNU-44 were used as internal controls for RNA and miRNA respectively. 
High COX-2 expressing cell lines, MCF7-COX-2 and MDAMB231, showed high 
expression of miR-526b and miR-655 and low expression of CPEB2. (*: p<0.05, **: 
p<0.005, ***: p<0.0005) indicates a significant difference compared to MCF7 cells (one-
way ANOVA, Tukey‘s post hoc test, n=3). 
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3.2 Validation of CPEB2 knockdown (KD) with small interfering RNA (siRNA) 
MCF7 cells (ER+/PR+/HER2-) are low in COX-2, miR-655, miR-526b and high in 
CPEB2 mRNA expression. To investigate the functional role of CPEB2 in vitro, CPEB2 
expression was suppressed in MCF7 cells using siRNAs targeting CPEB2 and a universal 
scrambled siRNA control at 1µM concentrations. The resulting cell lines were labeled as 
MCF7-CPEB2 KD and MCF7-Scrambled. CPEB2 expression was quantified in non-
transfected (MCF7-Parental), MCF7-Scrambled and MCF7-CPEB2 KD using real-time 
PCR (2
-ΔΔCT
). MCF7-CPEB2 KD cells demonstrated significant down-regulation of 
CPEB2 compared to Parental cells (Figure 3).  
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Figure 3. MCF7 cells transfected with CPEB2 siRNA have significantly lower 
expression of CPEB2  
MCF7 cells were transfected with human CPEB2 siRNA (1 µM) and universal scrambled 
negative control siRNA. Resulting cell line, MCF7-CPEB2 KD showed 70% down-
regulation of CPEB2 compared to non-transfected MCF7-Parental cell line using relative 
quantification of real-time PCR data (2
-ΔΔCT
). The data are presented as average fold 
change normalized to MCF7-Parental ± SEM for 4 independent experiments. RPL5 was 
used as an internal control. (*) indicates a significant difference (p<0.0001) compared to 
parental cells (one-way ANOVA, Tukey‘s post hoc test). 
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3.3 Knockdown of CPEB2 increased breast cancer cell migration and invasion 
MCF7-COX-2, MCF7-526b and MCF7-655 cells showed increased migration and 
invasion compared to control MCF7 cells (Dunn et al., 2014; Majumder et al., 2015; 
Majumder, Postovit, et al., 2014). Therefore, our putative target CPEB2 might also play a 
role in cell migration and invasion. To assess the migratory ability of breast cancer cells 
with reduced CPEB2, MCF7-CPEB2 KD cells were used in transwell migration assays. 
The transwell assay is a method of measuring cell migration in a 2-D environment, 
through a semi-permeable membrane. MCF7-CPEB2 KD cells had significantly 
increased migratory capacity compared to MCF7-Parental or Scrambled controls (Figure 
4). 
Furthermore, MCF7-CPEB2 KD cells had significantly increased invasion capacity 
(Figure 5) using a complementary transwell invasion method through matrigel coated 
transwell inserts. Here, the ability of cells to degrade this ‗basement membrane‘ layer and 
pass through the membrane was evaluated. Taking these results together, CPEB2 
knockdown promotes migration and invasion in vitro. 
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Figure 4. Knockdown of CPEB2 increased migration in MCF7 cells 
MCF7-Parental, MCF7-Scrambled or MCF7-CPEB2 KD cells were plated in the upper 
chamber of transwell inserts and incubated for 24 hours. The cells that passed through the 
insert membrane were stained with Eosin and Thiasine, and counted by microscopy. A. 
Images of migration transwell inserts showing number of migratory cells (scale bar: 100 
µm). B. MCF7-CPEB2 KD cells had a 2-fold increase in migration compared to MCF7-
Parental cells. There was no difference in migration between MCF7-Parental and MCF7-
Scrambled cells. Data are represented as average fold change normalized to MCF7-
Parental ± SEM for 3 experiments. (*) indicates a significant difference (p=0.0038) 
compared to parental cells (one-way ANOVA, Tukey‘s post hoc test). 
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Figure 5. Knockdown of CPEB2 increased invasion in MCF7 cells 
MCF7-Parental, MCF7-Scrambled and MCF7-CPEB2 KD cells were plated in the upper 
chamber of transwell inserts coated with matrigel. After 48 hours, the cells that degraded 
the layer of matrigel and passed through the insert membrane were stained with Eosin 
and Thiasine, and counted. MCF7-CPEB2 KD had a 2.4-fold increase in invasion 
compared to MCF7-Parental cells. There was no significant difference in invasion 
between MCF7-Parental and Scrambled cells. Data are represented as average fold 
change normalized to MCF7-Parental ± SEM for 3 experiments. (*) indicates a 
significant difference (p=0.0127) compared to parental cells (one-way ANOVA, Tukey‘s 
post hoc test). 
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3.4 Knockdown of CPEB2 has no effect on breast cancer cell proliferation 
To delineate the role of CPEB2 in cell proliferation, a BrdU incorporation assay was 
performed. BrdU is integrated into newly synthesizing DNA during replication. The 
amount of BrdU present in the cells is then used as a measure of cellular proliferation. 
There was no significant difference in the amount of BrdU incorporated between Parental 
and CPEB2 KD cells (Figure 6). Therefore, we concluded that CPEB2 did not play a 
major role in cellular proliferation. 
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Figure 6. MCF7-CPEB2 KD cells have no change in cell proliferation 
MCF7-Parental, MCF7-Scrambled and MCF7-CPEB2 KD cells were plated in 96 well 
plates. BrdU incorporation was measured after 6 hours of incubation. MCF7-CPEB2 KD 
cells showed no significant change (1.18 fold increase) in the average BrdU incorporated 
into cells compared to MCF7-Parental cells. The data are represented as average fold 
change normalized to MCF7-Parental ± SEM for 3 experiments (One-way ANOVA, 
p=0.11). 
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3.5 Down-regulation of CPEB2 promoted an EMT phenotype 
Previous work done in this laboratory has determined that over-expressing miR-526b in 
vitro decreased expression of CDH1 and up-regulated mesenchymal markers Twist1, 
VIM, and Snail1 (Majumder et al., 2015). Furthermore, as shown in Figure 4, down-
regulating CPEB2 resulted in increased migration ability. To test whether CPEB2 KD 
was associated with an EMT switch, different epithelial and mesenchymal markers were 
tested (mRNA and IF). CPEB2 KD resulted in an increase in Twist1 and ZEB1, however 
there was no change in Snai1 and VIM (Figure 7). Figure 8 validated that Twist1 
expression increased at the protein level as well. At the same time, E-Cadherin levels 
decreased with CPEB2 KD (Figure 9). Collectively, we determined that CPEB2 KD 
decreases E-Cadherin protein and increases Twist1 and Zeb1 in MCF7 cells, thus has an 
important role in EMT. 
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Figure 7. MCF7-CPEB2 KD cells have increased expression of mesenchymal 
marker Twist1 
MCF7 cells transfected with human CPEB2 siRNA were compared to scrambled control 
transfected cells for mesenchymal markers using relative quantification by real-time PCR 
(2
-ΔΔCT
). MCF7-CPEB2 KD cells had a 1.6 fold increase in Twist1 expression compared 
to MCF7-Scrambled cells (p=0.0104). Furthermore there was a trend towards increased 
ZEB1 in CPEB2 KD cells (p=0.0556). There was no change in SNAI1 and VIM between 
CPEB2 KD and control groups. The data are presented as average fold change 
normalized to MCF7-Scrambled ± SEM for 3 experiments. RPL5 was used as an internal 
control. (*) indicates a significant difference (unpaired t-test). 
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Figure 8. MCF7-CPEB2 KD cells have increased expression of mesenchymal 
marker Twist1 
A. Twist1 antibody (1:250 in 4% BSA in PBS) was added onto MCF7-Scrambled and 
CPEB2 KD cells fixed onto coverslips. Cells were imaged using Olympus FV1000. 
Representative images are shown at the same magnification (scale bar: 100 µm, bottom 
right panel). DAPI is shown as blue nuclei staining and Twist1 is shown as green 
cytoplasmic staining, and merged shows both. B. Quantification of representative 
immuno-fluorescence images was performed using ImageJ. Data are presented as the 
average of raw integrated density divided by cell area. MCF7-CPEB2 KD cells had a 2.6 
fold increase in Twist1 intensity compared to MCF7-Scrambled. The data are presented 
as average fold change normalized to MCF7-Scrambled ± SEM. (*) indicates a 
significant difference compared to Scrambled (unpaired t-test p<0.0001). 
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Figure 9. MCF7-CPEB2 KD cells have decreased expression of epithelial marker E-
Cadherin 
A. E-Cadherin antibody (1:250 in 4% BSA in PBS) was added onto MCF7-Scrambled 
and CPEB2 KD cells fixed onto coverslips. Cells were imaged using Olympus FV1000. 
Representative images are shown at the same magnification (scale bar: 100 µm, bottom 
right panel). DAPI is shown as blue nuclei staining and E-Cadherin is shown as green cell 
membrane staining, and merged shows both. B. Quantification of immuno-fluorescence 
pictures using ImageJ. Data are represented as the average of raw integrated density 
divided by cell area. MCF7-CPEB2 KD cells had 67% reduced E-Cadherin staining 
intensity compared to MCF7-Scrambled. Data are presented as average fold change 
normalized to MCF7-Scrambled ± SEM. (*) indicates a significant difference (unpaired t-
test p<0.0001). 
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3.6 Down-regulation of CPEB2 stimulated a SLC phenotype 
MCF7-COX-2 cells demonstrated higher proportion of ALDH
high
CD44
+
 cells, increased 
tumoursphere forming ability when cultured under ultra-low attachment conditions and 
higher expression of miR-655 and miR-526b compared to MCF7-Mock transfected cell 
(Majumder, Postovit, et al., 2014). Furthermore, MCF7-526b cells cultured in 6 well 
ultra-low attachment plates demonstrated higher spheroid formation efficiency than 
MCF7-Mock cells (Majumder et al., 2015). Because these results suggest increased SLC 
phenotype in MCF7-COX2 and MCF7-526b cells, we next investigated the role of 
CPEB2 KD on SLC phenotype. 
CPEB2 siRNA transfected cells were maintained in non-adherent conditions for 8 days. 
Real-time PCR demonstrated that MCF7-CPEB2 KD cells retained reduced CPEB2 
expression compared to MCF7-Scrambled cells for the duration of the spheroid formation 
assay (8 days, Figure 10). MCF7-CPEB2 KD cells demonstrated higher spheroid 
formation efficiency compared to scrambled control cells (Figure 11). Different markers 
for SLC were also tested for MCF7-CPEB2 KD and MCF7-Scrambled cells cultured in 
monolayer and tumoursphere conditions. MCF7-CPEB2 KD cells showed a higher 
proportion of ALDH1 positive cells in monolayers compared to scrambled controls 
(Figure 12). In addition, Figure 13 demonstrates that CPEB2 KD tumourspheres also 
retained higher expression of ALDH1. CPEB2 KD cells also showed higher Nanog 
expression in monolayer and tumourspheres (Figure 14 and 15). Furthermore, SOX-2 
expression was demonstrated to be higher in CPEB2 KD tumourspheres compared to 
scrambled control tumourspheres (Figure 16). Collectively, we demonstrated that CPEB2 
KD promotes a SLC phenotype, with increased spheroid formation efficiency and 
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expression of pluripotency markers Nanog, SOX-2 and ALDH1.
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Figure 10. Eight days after siRNA transfection, MCF7-CPEB2 KD cells retained 
lower expression of CPEB2 
MCF7 cells were transfected with human CPEB2 siRNA (1 µM) and universal scrambled 
control siRNA. Eight days after transfection, MCF7-CPEB2 KD demonstrated a 45% 
reduction in CPEB2 compared to MCF7-Scrambled cells using relative quantification of 
real-time PCR (2
-ΔΔCT
). Data are presented as average fold change normalized to MCF7-
Scrambled ± SEM for 3 experimental replicates. RPL5 was used as an internal control. 
(*) indicates a significant difference compared to control cells (unpaired t-test, 
p=0.0007). 
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Figure 11. MCF7-CPEB2 KD cells demonstrated increased spheroid formation 
MCF7-Scrambled and MCF7-CPEB2 KD cells were plated in 96 well ultra-low 
attachment plates at a concentration of 5 cells per well. After 7 days, spheroids greater 
than 60 µm were counted manually under bright-field microscopy. Spheroid formation 
efficiency was calculated as the ratio of number of spheroids formed to number of cells 
plated. MCF7-CPEB2 KD cells had a higher SFE (0.13) than MCF7-Scrambled cells 
(0.10). (*) indicates a significant difference (unpaired t-test, p=0.0411, n=3). 
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Figure 12. MCF7-CPEB2 KD cells grown in monolayer have increased expression of 
ALDH1 
A. ALDH1 antibody (1:300 in 4% BSA in PBS) was added onto MCF7-Scrambled and 
CPEB2 KD cells grown in monolayers. Cells were imaged using an Olympus FV1000 
fluorescent microscope. All image panels are at the same magnification (scale bar: 100 
µm, bottom right panel). DAPI is shown as blue nuclei staining and ALDH1 is shown as 
green cytoplasmic staining, and merged shows both. B. Quantification of ALDH1 
expression. Data are presented as ratio of positive cells to the total number of DAPI+ 
cells normalized to MCF7-Scrambled controls. MCF7-CPEB2 KD cells demonstrated a 
3.8 fold increase in ALDH1 positive cells compared to MCF7-Scrambled cells. (*) 
indicates a significant difference (unpaired t-test, p=0.0389). 
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Figure 13. MCF7-CPEB2 KD tumourspheres have increased expression of ALDH1 
A. ALDH1 antibody (1:300 in 4% BSA in PBS) was added onto MCF7-Scrambled and 
CPEB2 KD tumourspheres. Cells were imaged using an Olympus FV1000 fluorescent 
microscope. All image panels are at the same magnification (scale bar: 100 µm, bottom 
right panel). DAPI is shown as blue nuclei staining and ALDH1 is shown as green 
cytoplasmic staining, and merged shows both. B. Quantification of ALDH1 expression. 
Data are presented as ratio of positive cells to the total number of DAPI+ cells 
normalized to MCF7-Scrambled controls. MCF7-CPEB2 KD cells demonstrated a 2.6 
fold increase in ALDH1 positive cells compared to MCF7-Scrambled. (*) indicates a 
significant difference (unpaired t-test, p=0.0428). 
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Figure 14. MCF7-CPEB2 KD cells grown in monolayer demonstrated increased 
Nanog expression 
A. Nanog antibody (1:300 in 4% BSA in PBS) was added onto MCF7-Scrambled and 
CPEB2 KD cells grown in monolayers. Cells were imaged using an Olympus FV1000 
fluorescent microscope. All image panels are at the same magnification (scale bar: 100 
µm, bottom right panel). DAPI is shown as blue nuclei staining and Nanog is shown as 
green nuclear staining, and merged shows both. B. Quantification of Nanog expression. 
Data are presented as ratio of positive cells to the total number of DAPI+ cells 
normalized to MCF7-Scrambled controls. MCF7-CPEB2 KD cells demonstrated 6.5 fold 
increase in Nanog positive cells compared to MCF7-Scrambled. (*) indicates a 
significant difference (unpaired t-test, p=0.0064). 
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Figure 15. MCF7-CPEB2 KD tumourspheres demonstrated increased Nanog 
expression 
A. Nanog antibody (1:300 in 4% BSA in PBS) was added onto MCF7-Scrambled and 
CPEB2 KD tumourspheres. Cells were imaged using an Olympus FV1000 fluorescent 
microscope. All image panels are at the same magnification (scale bar: 100 µm, bottom 
right panel). DAPI is shown as blue nuclei staining and Nanog is shown as green nuclear 
staining, and merged shows both. B. Quantification of Nanog expression. Data are 
presented as ratio of positive cells to the total number of DAPI+ cells normalized to 
MCF7-Scrambled controls.  MCF7-CPEB2 KD cells demonstrated a 4.1 fold increase in 
Nanog positive cells compared to MCF7-Scrambled. (*) indicates a significant difference 
(unpaired t-test, p< 0.0001). 
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Figure 16. MCF7-CPEB2 KD tumourspheres have increased SOX-2 expression 
A. SOX-2 antibody (1:300 in 4% BSA in PBS) was added onto MCF7-Scrambled and 
CPEB2 KD tumourspheres. Cells were imaged using an Olympus FV1000 fluorescent 
microscope. All image panels are at the same magnification (scale bar: 100 µm, bottom 
right panel). DAPI is shown as blue nuclei staining and SOX-2 is shown as green nuclear 
staining, and merged shows both. B. Quantification of SOX-2 staining. Data are 
presented as ratio of positive cells to the total number of DAPI+ cells normalized to 
MCF7-Scrambled controls. MCF7-CPEB2 KD cells demonstrated a 4.4 fold increase in 
Nanog positive cells compared to MCF7-Scrambled. (*) indicates a significant difference 
(unpaired t-test, p=0.002). 
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3.7 COX-2 and EP4 inhibition increased CPEB2 expression 
We have previously shown that blocking COX-2 activity and EP4 signaling resulted in 
reduced angiogenesis, lymphangiogenesis, tumour growth and metastasis to the lungs 
(Xin et al., 2012). Furthermore, MCF7 cells treated with PGE2 and selective EP4 agonist 
demonstrated an increase in miR-655 and miR-526b levels, while treatment with COX-2 
inhibitor and EP4 antagonists resulted in decreased miRNA  levels (Majumder et al., 
2015; Majumder, Postovit, et al., 2014). To examine the ability of COX-2 activity and 
EP4 signaling to modulate CPEB2 expression, MCF7-COX-2 cells were treated with 
selective COX-2 inhibitor (Celecoxib) and EP4 antagonist (ONO-AE3-208, ONO), while 
MCF7 cells were treated with PGE2 (EP1-4 ligand) and EP4 agonist (PGE1OH). Figure 
17 demonstrates that MCF7-COX-2 cells treated with Celecoxib had significantly higher 
CPEB2 expressions at both 10 µM and 20 µM compared to DMSO treated cells. At the 
same time, MCF7-COX2 cells treated with ONO also had significantly higher expression 
of CPEB2 at 20 µM compared to DMSO treated cells (Figure 17). Surprisingly, MCF7 
cells treated with PGE2 and PGE1OH demonstrated no change in CPEB2 expression 
compared to EtOH treated controls (Figure 18). Therefore, we were able to demonstrate 
that only blocking COX-2 activity and EP4 signaling could modulate CPEB2 expression.  
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Figure 17. Cells treated with EP4 antagonist and COX-2 specific inhibitors have 
increased CPEB2 expression 
MCF7-COX-2 cells were treated with A. selective COX-2 inhibitor Celecoxib, or B. EP4 
Antagonist ONO-AE3-208 at two different concentrations (10 µM and 20 µM), and 
compared to DMSO (0.0003%) control after for 24 hours culture. MCF7-COX-2 cells 
treated with Celecoxib at 10 µM and 20 µM showed a 1.6 and 3.3 fold increase in 
CPEB2 expression compared to DMSO (one-way ANOVA, Tukey‘s post hoc test, 
p<0.0001). MCF7-COX-2 cells treated with ONO at 20 µM showed a 1.25 fold increase 
in CPEB2 expression compared to DMSO treated cells (one-way ANOVA, Tukey‘s post 
hoc test, p=0.0391). The data are presented as average fold change normalized to DMSO 
treated cells ± SEM for 3 experiments. (*) indicates a significant difference. 
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Figure 18. Cells treated with PGE2 and EP4 Agonist demonstrated no change in 
CPEB2 expression 
MCF7 cells were treated with 10 µM PGE2 (EP1-4 ligand), 10 µM PGE1OH (EP4 
agonist), and compared to 0.13% EtOH control after 24 hours culture. There were no 
significant changes in CPEB2 expression in either treatment. The data are presented as 
average fold change normalized to EtOH treated cells ± SEM for 3 experiments (one-way 
ANOVA, p=0.7065). 
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4 DISCUSSION AND CONCLUSIONS 
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4.1 Summary of Findings and Conclusions 
Objective 1: To investigate if there is an inverse relationship between expression levels of 
a) CPEB2 and COX-2 and b) CPEB2 and miR-655 or miR-526b in human breast cancer 
cell lines. 
Expression of COX-2, miR-655, miR-526b and CPEB2 were tested in MCF7, SKBR3, 
MDAMB231 and MCF7-COX2 cell lines. High COX-2 cell lines such as MCF7-COX-2 
and MDA-MB-231 demonstrated high expression of miR-655 and miR-526b and low 
expression of CPEB-2 compared to low COX-2 cell lines such as MCF7 and SKBR3. 
The observed association between high COX-2, high miRNA and low CPEB2 
expression, validates the inverse relationship demonstrated by the differential gene and 
miRNA microarray analysis (Majumder et al., 2015). 
 
Objective 2: To investigate the functional role of CPEB2 in human breast cancer. 
CPEB2 expression was down-regulated using siRNAs in MCF7 (low COX-2/miRNAs) 
cells. The resultant MCF7-CPEB2 KD cells demonstrated increased migration and 
invasion in transwell assays, with no change in cellular proliferation rates. Furthermore, 
CPEB2 down-regulation was also associated with an EMT phenotype where E-Cadherin 
protein decreased and Twist1 mRNA and protein increased. There was also an increase in 
ZEB1 mRNA. Additionally, MCF7-CPEB2 KD cells displayed increased tumoursphere 
forming ability in ultra-low attachment plates. When tested for different SLC-associated 
maker expression, CPEB2 KD cells had a higher frequency of ALDH1, Nanog and SOX-
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2 expressing cells. These data suggest that CPEB2 is anti-migratory and anti-invasive in 
vitro, and down-regulation of CPEB2 results in a more aggressive breast cancer 
phenotype. Thus, CPEB2 expression can also be implicated in the metastatic cascade 
during COX-2 mediated breast cancer progression. 
 
Objective 3: To investigate the effects of COX-2 inhibitor, and PGE2 (EP1-4 ligand), EP4 
agonist and antagonist treatments on CPEB2 levels. 
MCF7-COX-2 cells were first treated with Celecoxib (selective COX-2 inhibitor) and 
ONO-AE3-208 (selective EP4 antagonist), and DMSO control. Both treatments resulted 
in an increase in CPEB2 expression compared to DMSO treated cells, as expected. Thus 
CPEB2 expression in high COX-2 cells is dependent on both COX-2 and EP4 activity. 
Surprisingly, activating the EP receptors (with PGE2) and EP4 receptor (with selective 
agonist PGE1OH) in low COX-2/high CPEB2 cells resulted in no significant change in 
CPEB2 expression. These data suggest that down-regulation of CPEB2 in high CPEB2 
expressing cells is possibly regulated by alternate signaling pathways outside of EP 
activity. Therefore, it is likely that cells might have different mechanisms of up-
regulating and down-regulating CPEB2. 
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4.2 Contribution to the Current Field of Research 
The role of COX-2 in cancer progression is widely recognized. In vivo mouse studies 
have shown that deletion of COX-2 results in reduced intestinal tumourigenesis (Oshima 
et al., 1996). At the same time, patients who were treated with COX-2 inhibitors or low-
dose aspirin demonstrated a decrease in the number of polyps formed and fatal colon 
cancer (Thun et al., 1991). In breast cancer, high COX-2 has been associated with an 
aggressive breast cancer phenotype, with increased invasion, and decreased disease free 
survival rates (Barnes, Haywood, Flint, Knox, & Bundred, 2006; Larkins, Nowell, Singh, 
& Sanford, 2006; Majumder, Postovit, et al., 2014). Additionally, COX-2 inhibitors in 
breast cancer displayed chemo-preventive properties (Harris et al., 2000; Harris, 2009; 
Majumder, Xin, Liu, Girish, et al., 2014; Xin et al., 2012). Unfortunately, use of COX-2 
inhibitors for a prolonged period revealed serious thromboembolic side-effects in a subset 
of patients (Fitzgerald, 2004; Nussmeier et al., 2005). Therefore, our lab is investigating 
downstream effectors of the COX-2 pathway as potential therapeutic targets in high 
COX-2 breast cancer. 
Our laboratory has previously established that COX-2 exerts its effects through over-
production of PGE2 activating the prostanoid receptor EP4 (Majumder, Xin, Liu, Girish, 
et al., 2014; Timoshenko et al., 2004, 2003; Xin et al., 2012). Both increased COX-2 
activity and stimulation of EP4 resulted in increased expression of miR-655 and miR-
526b in breast cancer cells. Both miRNAs revealed similar oncogenic properties 
including SLC induction in vitro (Dunn et al., 2014; Majumder et al., 2015).  MiRNAs 
play an important role in cancer. These small non-coding RNA molecules bind and 
down-regulate the expression of certain target genes. Since we have found both miR-
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526b and miR-655 to be oncogenic in our lab, by extension we believe that their target 
gene, CPEB2, should have tumour-suppressor-like functions. The underlying purpose of 
this study was to identify the functional role of CPEB2 in breast cancer progression. 
 
4.3 Role of CPEB2 in breast cancer cell migration, invasion, SLC induction and 
EMT 
We observed that high COX2, high miRNA breast cancer cell lines have decreased 
CPEB2. Both COX-2 induced miR-655 and miR-526b have been shown to increase 
cellular migration and invasion. Therefore, we predicted that the gene target CPEB2 
should be anti-migratory and anti-invasive. As expected CPEB2 KD cells showed 
increased migration and invasion in transwell assays, supporting our hypothesis that 
CPEB2 plays an anti-oncogenic role in breast cancer. Interestingly, a recent study has 
shown that miR-550a is pro-metastatic in hepatocellular carcinoma (Tian et al., 2012). 
MiR-550a binds to and down-regulates CPEB4. Gain-of function studies have 
demonstrated that CPEB4 is able to suppress miR-550a induced migration and invasion 
(Tian et al., 2012). Additionally, miR-92 and miR-26 both bind to the 3‘UTR of CPEB2, 
suggesting that CPEB2 contains functional miRNA binding sites (Morgan et al., 2010). 
In a previous study, CPEB1 was shown to be SLC suppressive. Ectopic CPEB1 
expression induced differentiation of glioma stem cells and reduced spheroid formation 
(Yin et al., 2014). In addition, CPEB1 was shown to reduce the expression of SLC 
markers SOX-2 and Nestin and increase expression of differentiation marker GFAP (Yin 
et al., 2014). In the present project, we extensively explored the ability of CPEB2 KD to 
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increase SLC properties of breast cancer cells in vitro. We found that CPEB2 KD cells 
had increased ability to form spheroids, and displayed increased expression of SOX-2, 
Nanog and ALDH1. Thus, we demonstrate for the first time that CPEB2 suppresses SLC 
phenotype in human breast cancer. 
EMT has also been implicated with increased invasion, metastasis and cancer progression 
(Thiery, 2002), and has more recently associated with SLCs (Mani et al., 2008). Cells 
transfected with Snail and Twist1 over-expressing plasmids had increased tumoursphere 
forming ability and were enriched for stem cell markers indicated by a CD44
high
/CD24
low
 
cells. Conversely, mammary epithelial cells sorted for CD44
high
/CD24
low
 population 
showed high expression levels of EMT-associated genes, for instance low levels of 
CDH1 and high levels of CDH2 (Mani et al., 2008). In our studies, we found that CPEB2 
KD decreased expression of E-Cadherin protein and increased expression of 
mesenchymal marker Twist1. Thus, CPEB2 KD cells were enriched in both SLCs and 
resembled an EMT-like phenotype. A previous study demonstrated that CPEB2 is a 
negative regulator of EMT progression and Twist1 expression (Nairismägi et al., 2012). 
EMT phenotype is considered to be a promoter of cell motility. Present observation of 
increased migration may be a consequence of EMT in CPEB2 KD cells. Taken together, 
CPEB2 stimulation might represent an important target for the prevention of cancer 
progression. 
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4.4 Role of COX-2 activity, EP4 Agonists and Antagonists in breast cancer 
Multiple studies from other laboratories and ours have demonstrated the importance of 
EP4 signaling in COX-2 mediated breast cancer progression. EP4 is a downstream target 
in the COX-2 pathway that avoids the disruption of prostanoids such as PGI2 and 
associated adverse cardiovascular events (Graham, 2006). As such EP4 represents a 
promising therapeutic target in breast cancer. EP4 has previously been shown to regulate 
proliferation, invasion and immune-suppression of natural killer cells (Ma et al., 2013; 
Robertson et al., 2008). Furthermore, the EP4 receptor has been linked to angiogenesis, 
lymphangiogenesis and metastasis (Timoshenko et al., 2006; Xin et al., 2012). COX-2 
up-regulation of EP4 mediated signaling also increases the expression of oncogenic miR-
526b and miR-655 (Majumder et al., 2015; Majumder, Postovit, et al., 2014). By 
extension, we expected that EP4 antagonists should increase CPEB2 levels in high COX-
2 cells. MCF7-COX-2 cells were treated with Celecoxib (selective COX-2 inhibitor) and 
ONO-AE3-208 (EP4 antagonist). As expected, both treatments in high COX-2 cells 
displayed high CPEB2 mRNA levels. Interestingly, Celecoxib induced a greater up-
regulation of CPEB2 than ONO-AE3-208 suggesting that CPEB2 expression might be 
modulated through other EP receptors as well. Surprisingly, treatment with PGE2 and 
EP4 agonist in high CPEB2 MCF7 cells could not suppress CPEB2 expression. Thus, it 
is likely that EP4 signaling is just one of the players regulating CPEB2 expression in 
CPEB2 high cells, suggesting that CPEB2 up-regulation and down-regulation have 
different mechanisms.  Since we could demonstrated an increase in CPEB2 expression 
following EP4 antagonist treatment, low CPEB2 might be used as a marker for EP4 
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targeted therapy used in conjunction with traditional therapy in high COX-2 breast 
cancer.  
 
4.5 Limitations of the Study 
CPEB2 gene manipulations were only tested in one cell line, MCF7, which is a poorly 
metastatic breast cancer cell line. Ideally inclusion of a non-tumourgenic mammary 
epithelial cell line such as MCF10A would strengthen the present study. Furthermore, a 
naturally occurring CPEB2 low cell line, such as MDAMB231, could also have been 
manipulated to examine CPEB2 gain-of-function effects. Another limitation of the 
present study is that CPEB2 levels were measured at the RNA level and not protein level. 
Unfortunately, at this time there is no reliable and commercially available antibody for 
CPEB2, therefore changes at the protein level could not be addressed. There are currently 
six different predicted isoforms of CPEB2 (CPEB2 A-F, Table 4). Thus, deciphering the 
role of each isoform will be an interesting and important part of future studies to 
understand the role of CPEB2 in breast cancer.  
Our proliferation assay using 6 h BrdU uptake did not reveal any change in proliferation 
in CPEB2 KD cells compared to control cells. The results would have been strengthened 
by an additional assay such as temporal changes in viable cell numbers for a longer 
period such as 72 hours using a MTT assay. 
To examine the SLC phenotype, an in vitro assay for spheroid formation efficiency was 
conducted. This was supplemented with immuno-fluorescence images at both monolayer 
and tumoursphere for SLC markers ALDH1, Nanog and SOX-2. This section can be 
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further improved by an examination of SLC markers at the transcription level and 
measurements of ALDH activity by flow cytometry. 
Another aspect of the project that can be further explored is the role of the miR-655 and 
miR-526b on CPEB2 gene manipulation. By looking at the different breast cancer cell 
lines, we can conclude that high COX-2, high miRNA cell lines have low CPEB2 
expression. However, we cannot assume that the miRNAs directly target CPEB2. A 
luciferase reporter assay can properly validate that the miRNAs target and down-regulate 
CPEB2 expression.  
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4.6 Future Directions: Role of CPEB2 in Hypoxia 
Cancer cells with a rapid proliferation rate expand into a tumour mass. Eventually the 
middle of the mass experiences cell death as the rate of oxygen diffusion is not able to 
keep up with the rapidly expanding mass (Brahimi-Horn, Chiche, & Pouysségur, 2007). 
One mechanism through which cancer cells adapt to low oxygen levels is by the up-
regulation of (HIF)-1. HIF-1 is composed of two transcription factors, inducible HIF-1α 
and constitutively expressed HIF-1β. These transcription factors regulate a number of 
genes that promote cell-survival such as angiongenic factors like VEGF (Brahimi-Horn et 
al., 2007; Jung, Isaacs, Lee, Trepel, & Neckers, 2003).  
Colorectal carcinoma cell lines exposed to hypoxic condition demonstrated an expected 
increase HIF-1α (Kaidi, Qualtrough, Williams, & Paraskeva, 2006). Interestingly COX-2 
protein was also up-regulated in these hypoxic conditions (Kaidi et al., 2006). A 
complementary study determined that COX-2 contains a functional binding site for HIF-
1α (Csiki et al., 2006; Kaidi et al., 2006). Furthermore, stimulation with PGE2 has been 
shown to increase HIF-1α protein (Csiki et al., 2006). These results establish a link 
between COX-2 and HIF-1α. 
As mentioned previously, CPEB2 binds to the 3‘ UTR of HIF-1α and modulates 
translation of the protein (Chen & Huang, 2012; Hägele et al., 2009). In normal 
conditions, CPEB2 interacts with eEF2 and the 3‘UTR of HIF-1α, to suppress translation 
of the protein (Chen & Huang, 2012). In stressed conditions, CPEB2 dissociates from 
eEF2 and HIF-1α, allowing the translation of HIF-1α protein (Chen & Huang, 2012).  
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Taking the results from our study into account, it is possible that COX-2 up-regulation 
suppresses CPEB2, via PGE2, EP4 and oncogenic miR-526b and miR-655, and by doing 
so increases HIF-1α production in breast cancer. HIF-1α has been implicated in a positive 
feedback loop, where it up-regulates COX-2. This in turn can suppress CPEB2 levels and 
maintain translation of HIF-1α protein. Therefore, it would be interesting to test if there is 
increased COX-2, decreased CPEB2 and increased HIF-1α in a hypoxic environment. 
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Figure 19. Possible mechanism of COX-2, CPEB2 and HIF-1α Pathway in Hypoxia 
Up-regulation of COX-2 enzyme results in increased prostanoid production, more 
specifically increased PGE2. PGE2 can bind to four EP receptors, including EP4. 
Increased EP4 signaling results in the production of two oncogenic miRNAs in breast 
cancer, miR-655 and miR-526b. Both oncogenic miRNAs have target sites on CPEB2. It 
is predicted that increased miRNA production results in decreased CPEB2 expression.  
CPEB2 is a translational repressor of HIF-1α. With reduced CPEB2 levels, repression of 
HIF-1α is alleviated. HIF-1α has binding sites on COX-2, and participates in a feed 
forward loop which results in increased COX-2 production (Jung et al., 2003; Kaidi et al., 
2006; Majumder et al., 2015).  
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4.7 Conclusions 
In this study it was observed that high COX-2 and high miRNA (miR-655 and miR-526b) 
expressing breast cancer cells lines have low CPEB2 expression. As determined by in 
vitro assays, CPEB2 KD cells revealed increased cellular migration and invasion, without 
any effect on proliferation. For the first time, we showed that CPEB2 KD has a role in 
SLC induction, indicated by increased tumoursphere formation and expression of SLC 
markers ALDH1, Nanog and SOX-2. Also, CPEB2 KD cells exhibited EMT 
demonstrated by reduced E-Cadherin protein levels and increased Twist1 expression. Our 
results also reveal that CPEB2 expression could be reduced by blocking EP4 signaling 
with antagonists. These results suggest that CPEB2 is a tumour-suppressor-like gene and 
down-regulation of this gene results in an aggressive breast cancer phenotype. 
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Table 1:  Summary of breast cancer cell lines used in this project (ATCC, 2015; 
Chavez, Garimella, & Lipkowitz, 2010; Hackett et al., 1977; Holliday & Speirs, 
2011; Kao et al., 2009; Lehmann et al., 2011) 
Cell Line Classification 
Estrogen 
receptor 
(ER) 
Progesterone 
receptor 
(PR) 
HER2 Cell Type Disease Tissue 
HS578T Basal B 
— — — 
epithelial adenocarcinoma 
mammary 
gland/breast 
MCF7 Luminal A 
+ + — 
epithelial adenocarcinoma 
mammary gland, 
breast; derived from 
metastatic site: 
pleural effusion 
MDAMB231 Basal B 
— — — 
epithelial adenocarcinoma 
mammary 
gland/breast; derived 
from metastatic site: 
pleural effusion 
SKBR3 HER2 
— — + 
epithelial adenocarcinoma 
mammary 
gland/breast; derived 
from metastatic site: 
pleural effusion 
T47D Luminal A 
+ + — 
epithelial ductal carcinoma 
mammary gland; 
derived from 
metastatic site: 
pleural effusion 
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Table 2: Probes used for real-time PCR 
Probe Company Catalog 
Number 
Assay ID 
CPEB2 TaqMan® Gene Expression Assay Life Technologies 4331182 Hs01039673_m1 
hsa-miR-526b TaqMan® MicroRNA Assay Life Technologies 4427975 2382 
hsa-miR-655 TaqMan® MicroRNA Assay Life Technologies 4427975 1612 
PTGS-2 (COX2) TaqMan® Gene Expression Assay Life Technologies 4427975 Hs00153133_m1 
RNU44 TaqMan® Gene Expression Assay Life Technologies 4427975 1094 
RNU48 TaqMan® MicroRNA Assay Life Technologies 4427975 1006 
RPL5 TaqMan® Gene Expression Assay Life Technologies 4331182 Hs03044958_g1 
SNAI1 TaqMan® Gene Expression Assay Life Technologies 4331182 Hs00195591_m1 
TWIST1 TaqMan® Gene Expression Assay Life Technologies 4331182 Hs01675818_s1 
VIM (Vimentin) TaqMan® Gene Expression Assay Life Technologies 4331182 Hs00185584_m1 
ZEB1TaqMan® Gene Expression Assay Life Technologies 4331182 Hs00232783_m1 
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Table 3: Antibodies used for IF 
Antibody Raised in Dilution 
(1:x) 
Company Catalog 
Number 
E-Cadherin Rabbit 1000 Cell Signaling Technology 31955 
SOX-2 Mouse 300 BD Biosciences 561593 
Twist1 Rabbit 500 Santa Cruz Biotechnology SC_15393 
Vimentin Mouse 500 EMD Millipore MAB3400 
CF488A anti-Mouse IgG 
(H+L) Goat 400 Biotium 20018-1 
CF488A anti-Rabbit IgG 
(H+L) Goat 400 Biotium 20019-1 
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Table 4: CPEB2 Isoforms based on BLAST and UniProt (Universal Protein 
Resource) search. All isoforms are compared to CPEB2 isoform D 
Isoforms 
Nucleic 
acids 
Amino 
acids 
Difference from 
isoform D 
Molecular Weight 
(kDa) 
isoform D  6878 bp  1034 aa  The same  109.8 kDa  
isoform A  6764 bp  559 aa  
Missing sequences 
1950-2034 
61.7 kDa  
isoform B  6854 bp  589 aa  
Missing sequences 
2175-2199  
64.9 kDa  
isoform C  6797 bp  1007 aa  
Missing sequences 
1950-2034  
106.9 kDa  
isoform E  6788 bp  1007 aa  
Missing sequences 
1950-2034 
106.9 kDa  
isoform F  6773 bp  562 aa  
Missing sequences 
1950-2034 
62.1 kDa  
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Table 5: Abstract of COX-2/EP4/Notch-Wnt Axis in Breast Cancer Cell Induction 
Paper (Majumder et al. submitted Oncogene)  
 
102 
 
CURRICULUM VITAE  
 
Name:   Asma Hasan 
 
Post-secondary  Bachelor of Science 
Education and  Honors Specialization in Biology 
Degrees:   The University of Western Ontario 
   London, Ontario Canada 
   2009-2013 
 
Masters in Science 
Department of Anatomy and Cell Biology 
The University of Western Ontario 
   London, Ontario Canada 
   2013-2015 
 
 
 
Honours and   Translational Breast Cancer Research Studentship (TBCRU) 
Awards:   funded in part by the Breast Cancer Society of Canada 
   2013-2015 
    
   CIHR-Inst of Community Support Travel Award in partnership 
with CIHR-Inst of Cancer Research 
2015 
    
Western Graduate Research Scholarship (WGRS) 
   2013-2015 
 
   CIHR-Inst of Community Support Travel Award in partnership 
with CIHR-Inst of Cancer Research 
2014 
    
   CIHR-STP Award in Cancer Research and Technology Transfer 
   (CaRTT) 
   2013-2014  
 
   CaRTT Summer Studentship 
   2013 
 
 
Related Work  Teaching Assistant 
Experience   The University of Western Ontario 
2015 
 
103 
 
Publications: 
Hasan A, Majumder M, Amiri M and Lala PK. ―The role of CPEB-2 in breast cancer 
progression,‖ Canadian Cancer Research Conference. Montreal QC, November 8 2015. 
 
Hasan A, Majumder M, Amiri M and Lala PK. ―The role of CPEB-2 in breast cancer,‖ 
Oncology Research and Education Day. London ON, June 26 2015. 
 
Hasan A, Majumder M, Amiri M and Lala PK. ―The functional role of CPEB-2 in breast 
cancer,‖ American Association of Anatomist Regional Meeting. London ON, May 30  
2015. 
 
Hasan A, Majumder M, Amiri M and Lala PK. ―The role of CPEB-2 in human breast 
cancer,‖ London Health Research Day. London ON, April 1 2015. 
  
Hasan A, Majumder M and Lala PK. ―The role of CPEB-2 in breast cancer,‖ San 
Antonio Breast Cancer Symposium. San Antonio TX USA, December 10 2014. 
  
Hasan A, Majumder M, and Lala PK. ―The role of cytoplasmic polyadenylation element 
binding protein (CPEB)-2 in breast cancer,‖ Anatomy and Cell Biology Research Day. 
London ON, October 2014. 
  
Hasan A, Majumder M and Lala PK. ―The role of CPEB-2 in breast cancer progression,‖ 
Oncology Research and Education Day. London ON, June 20 2014. 
  
Hasan A, Majumder M and Lala PK. ―The role of CPEB-2, miR-526b and miR-655 in 
human breast cancer,‖ London Health Research Day. London ON, March 18 2014. 
  
Hasan A, Majumder M, Landman E and Lala PK. ―The role of cytoplasmic 
polyadenylation element binding protein (CPEB)-2 in breast cancer,‖ Anatomy and Cell 
Biology Research Day. London ON, October 24 2013. 
